UROLOGIX

UROLOGIX

OOTC:ULGX
0.00
USD
+0.00
(+9,900.00%)
-0.22EPS
1.62MMarket Cap

Total Valuation

USD

As of March 31, 2015, UROLOGIX carries a market capitalization of 1.62M, placing it among publicly traded companies globally. Its enterprise value stands at 6.46M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap1.62M
Enterprise Value6.46M

Share Statistics

As of March 31, 2015, UROLOGIX has 21.28M shares outstanding.

Shares Outstanding21.28M

Valuation Ratios

These figures are as of March 31, 2015. The price-to-sales ratio is 0.13, and the price-to-book ratio stands at -0.20.

PS Ratio0.13
PB Ratio-0.20
P/TBV Ratio-0.17
P/FCF Ratio-5.60
P/OCF Ratio-6.24

Enterprise Valuation

These figures are as of March 31, 2015. The EV/Sales ratio of 0.53 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 6.46M versus a market cap of 1.62M, with the gap driven by net debt and cash on the balance sheet.

EV / Sales0.53

Financial Position

As of March 31, 2015, UROLOGIX maintains a current ratio of 0.56, meaning it holds 0.6x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is -66.13, indicating conservative leverage, while an interest coverage ratio of -5.78 demonstrates limited ability to service its debt obligations.

Current Ratio0.56
Quick Ratio0.31
Debt / Equity-66.13
Debt / EBITDA-1.55
Interest Coverage-5.78

Financial Efficiency

USD

These figures cover the twelve months ended March 31, 2015. Return on assets (ROA) is negative at -65.12, reflecting losses generated across the asset base. The company generates approximately 199,836.07 in revenue per employee across its workforce of 61.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 4.83 indicates how many times UROLOGIX sells and replaces its inventory over a year, a key working capital efficiency ratio.

Return on Assets (ROA)-65.12
Revenue Per Employee199,836.07
Employee Count61.00
Inventory Turnover4.83

Taxes

USD

Over the twelve months ended March 31, 2015, UROLOGIX recorded an income tax benefit of -53,000.00 rather than an expense, typically from losses, carryforwards, or the release of a tax provision. The company reported a pretax loss of -4.72M and -4.67M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

Income Tax-53,000.00

Income Statement

USD

Over the twelve months ended March 31, 2015, UROLOGIX generated 12.19M in revenue and converted that into -4.67M in net income, yielding earnings per share of -0.22. EBITDA reached -3.43M, while operating income came in at -1.00M.

Revenue12.19M
Gross Profit5.82M
Operating Income-1.00M
Pretax Income-4.72M
Net Income-4.67M
EBITDA-3.43M
EBIT-3.94M
Earnings Per Share (EPS)-0.22

Balance Sheet

USD

As of March 31, 2015, UROLOGIX holds 492,000.00 in cash and equivalents against 5.33M in total debt, resulting in a net debt position of 4.84M. Total book value stands at -8.06M, with working capital of -2.73M providing operational flexibility.

Cash & Cash Equivalents492,000.00
Total Debt5.33M
Net Debt4.84M
Equity (Book Value)-8.06M
Book Value Per Share-0.38
Working Capital-2.73M

Cash Flow

USD

UROLOGIX produced -263,000.00 in operating cash flow over the twelve months ended March 31, 2015. After subtracting -30,000.00 in capital expenditures, free cash flow totaled -293,000.00 - equivalent to -0.01 per share.

Operating Cash Flow-263,000.00
Capital Expenditures-30,000.00
Free Cash Flow-293,000.00
FCF Per Share-0.01

Margins

Over the twelve months ended March 31, 2015, UROLOGIX posted a gross margin of 47.74, reflecting its pricing power and cost economics. The operating margin of -8.24 and net profit margin of -38.29 provide insight into operational efficiency.

Gross Margin47.74
Operating Margin-8.24
Pretax Margin-38.73
Profit Margin-38.29
EBITDA Margin-28.18

Dividends & Yields

These figures cover the twelve months ended March 31, 2015. Free cash flow yield is negative at -17.85: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield reaches - -, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to UROLOGIX shareholders.

FCF Yield-17.85

Scores

As of March 31, 2015, UROLOGIX has an Altman Z-Score of -45.61, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score-45.61